COMPANY PROFILE

Amplimmune

Explore full profile

Leading Global Biologics R&D | MedImmune

Rockville, United StatesFounded 2006Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2013

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Amplimmune

Amplimmune is a biotechnology company focused on developing innovative immunotherapy solutions to treat cancer and autoimmune diseases. The company operates in the biopharmaceutical market, targeting healthcare providers and patients who require advanced therapeutic options. Amplimmune's business model revolves around research and development, leveraging cutting-edge science to create novel treatments that modulate the immune system. Revenue is generated through partnerships, licensing agreements, and the commercialization of its proprietary therapies. The company aims to push the boundaries of science to deliver life-changing medicines, ensuring high-quality medical and scientific information exchange. Amplimmune's commitment to innovation and patient care positions it as a key player in the biopharmaceutical industry.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2006
Headquarters: Rockville, United States
Employees: 6
Open positions: None listed
Dealroom signal: 23.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Immune System
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Aug 2013	$500M	$500M	MedImmune	—
SERIES A✓Equity / VC	Jan 2006	$20M	$80M	InterWest Partners · Wellcome Trust	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Amplimmune website traffic

Latest recorded traffic for Amplimmune is 0 monthly website visits.

Latest monthly visits0

Monthly website visitsNov 2017–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CPChangsen PharmaceuticalInnovative drug development for viral and autoimmune diseases	China	Operational	2	—	—
AIAxImmune IncA clinical-stage immuno-oncology drug for co-therapy with checkpoint inhibitors, enhancing anti-tumor activity and preventing recurrence	—	Operational
AZAzuririsDrug discovery venture specializing in immunology and oncology, leveraging seasoned industry expertise to develop life-saving therapies	Tokyo, Japan	Operational
CBCoultreon BiopharmaPrecision oral therapies for systemic inflammatory control	Leuven, Belgium	Operational
CTCytospire TherapeuticsHarnessing the immune system to create next-generation cancer treatments	London, United Kingdom	Operational
BIBioleapA platform for developing advanced multi-modal therapies in-silico to cure the most complex diseases	Cambridge, United Kingdom	Operational
SHShiftBioBiopharmaceutical company focused on developing natural nanoparticle (NNP)-based therapeutics for previously undruggable targets	Seoul, South Korea	Operational
TBTakis BiotechInvolved in the identification of new biomarkers and in the development of molecular diagnostic tests	Rome, Italy	Operational